A Study of Efimosfermin Alfa in Adults With Hepatic Impairment | MicrobiomeTrials← Back to trialsNCT07358546
A Study of Efimosfermin Alfa in Adults With Hepatic Impairment
RecruitingPHASE1INTERVENTIONAL
Trial Details
Start: 2026-03-13Est. Completion: 2027-10-13
Enrollment target: 32 participants Locations- GSK Investigational Site, Rialto, California, United States
- GSK Investigational Site, Tampa, Florida, United States
- GSK Investigational Site, San Antonio, Texas, United States
Other microbiome trials you might be interested in
Psoriatic Arthritis
While many studies examine Nonalcoholic fatty liver disease (NAFLD), little is known about its progression to high-risk …
San Diego, United StatesEst. completion Sep 1, 2027
NAFLD
This study aims to enroll a robust cohort of NAFLD patients who undergo Intragastric Balloon placement through a multidi…
Dallas, United StatesCompleted Dec 2026
The goal of this observational study is to identify the impact of incretin-based obesity medications (e.g., GLP-1 and GL…
Indianapolis, United StatesCompleted Dec 31, 2029